

XENOMICS INC
Form 10QSB/A
March 01, 2006

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

AMENDMENT NO. 2 TO FORM 10-QSB

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED: OCTOBER 31, 2005**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission file number 333-103083

XENOMICS, INC.

(Name of small business issuer in its charter)

Florida

04-3721895

(State or Other Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification No.)

420 Lexington Avenue, Suite 1701, New York, New York 10170

(Address of principal executive offices) (Zip Code)

(212) 297-0808

(Registrant's telephone number)

(Former Name, Former Address and Former Fiscal Year, if changed since last report)

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for past 90 days.

Yes No

Indicate by check mark whether registrant is a shell company (as defined in rule 12b-2 of the Exchange Act):

Yes No

As of December 19, 2005, the registrant had 18,604,300 shares of common stock, par value \$0.0001, outstanding.



XENOMICS, INC.
(A Development Stage Company)
Index to Condensed Consolidated Financial Statements

	<u>Page</u>
PART I – FINANCIAL INFORMATION	
Item 1.	<u>Condensed Consolidated Financial Statements:</u>
	<u>Unaudited Balance Sheet as of October 31, 2005 - Restated</u> 4
	<u>Unaudited Statements of Operations for the Three and Nine Months Ended October 31, 2005 and 2004 and the Period August 4, 1999 (Inception) to October 31, 2005 - Restated</u> 5
	<u>Unaudited Statements of Changes in Stockholders' Equity for the Period August 4, 1999 (Inception) to October 31, 2005 - Restated</u> 6
	<u>Unaudited Statements of Cash Flows for the Nine Months Ended October 31, 2005 and 2004 and the Period August 4, 1999 (Inception) to October 31, 2005 - Restated</u> 9
	<u>Notes to Unaudited Condensed Consolidated Financial Statements</u> 10
Item 2.	<u>Management's Discussion and Analysis or Plan of Operation</u> 16
Item 3.	<u>Controls and Procedures</u> 20
PART II – OTHER INFORMATION	
Item 6.	<u>Exhibits</u> 21
	<u>Signatures</u> 22

INTRODUCTORY NOTE

This Report on Amendment No. 2 to Form 10-QSB for Xenomics, Inc. (the "Company") may contain forward-looking statements. You can identify these statements by forward-looking words such as "may," "will," "expect," "intend," "anticipate," believe, "estimate" and "continue" or similar words. Forward-looking statements include information concerning possible or assumed future business success or financial results. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties set forth under "Risk Factors" in our Annual Report on Amendment No.2 to Form 10-KSB for the year ended January 31, 2005 and other periodic reports filed with the SEC. Accordingly, to the extent that this Quarterly Report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of the Company, please be advised that the Company's actual financial condition, operating results and business performance may differ materially from that projected or estimated by the Company in forward-looking statements.

EXPLANATORY NOTE

This Amendment No. 2 to Form 10-QSB includes restated unaudited condensed consolidated financial statements for the quarters ended October 31, 2005 and 2004, and for the period from inception (August 4, 1999) to October 31, 2005, in response to comments received by us from the Staff of the Securities and Exchange Commission. This Amendment speaks of the original filing of our Form 10-QSB and has not been updated to reflect events occurring subsequent to the original filing date.

PART I – FINANCIAL INFORMATION**Item 1. Condensed Consolidated Financial Statements****XENOMICS, INC.**

(A Development Stage Company)

CONDENSED CONSOLIDATED BALANCE SHEET - RESTATED**AS OF OCTOBER 31, 2005****(Unaudited)****ASSETS**

Current Assets:

Cash and cash equivalents	\$	5,090,177
Prepaid expenses		97,773
TOTAL CURRENT ASSETS		5,187,950

Property and equipment, net		90,514
Security deposits		55,698
	\$	5,334,162

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable	\$	68,972
Accrued expenses		32,500
TOTAL CURRENT LIABILITIES		101,472

Non-current liability:

Derivative financial instrument		418,474
---------------------------------	--	---------

Stockholders' equity:

Preferred stock, \$.001 par value, 20,000,000 shares authorized, 277,100 shares outstanding, designated as Series A Convertible Preferred Stock		2,203,915
Common stock, \$.0001 par value, authorized 100,000,000 shares, 18,604,300 issued and outstanding		1,860
Additional paid-in-capital		17,590,422
Deferred stock based compensation		(1,207,429)
Deficit accumulated during the development stage		(13,774,552)
		4,814,216
	\$	5,334,162

The accompanying notes are an integral part of these condensed consolidated financial statements.

XENOMICS, INC.
(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - RESTATED
(UNAUDITED)

	Three Months Ended October 31,		Nine Months Ended October 31,		August 4, 1999 (Inception) to October 31, 2005
	2005	2004	2005	2004	
Revenues	\$ 0	\$ 0	\$ 0	\$ 0	\$ 0
Costs and expenses:					
Research and development	366,555	301,622	959,363	469,796	3,249,690
General and administrative	627,634	42,402	2,155,814	44,405	2,822,056
Stock based compensation	161,458	545,311	3,429,172	706,641	7,534,878
Total costs and expenses	1,155,647	889,335	6,544,349	1,220,842	13,606,624
Loss from operations	(1,155,647)	(889,335)	(6,544,349)	(1,220,842)	(13,606,624)
Interest and investment income	7,633	3,971	53,443	3,971	73,478
Other (expense)	(27,710)	—	(44,014)	—	(44,014)
Derivative financial instrument income	179,663	—	148,611	—	148,611
Net loss	(996,061)	(885,364)	(6,386,309)	(1,216,871)	(13,428,549)
Preferred stock dividend	(23,794)	—	(23,794)	—	(23,794)
Accretion on Series A Preferred stock	—	—	(322,209)	—	(322,209)
Net loss applicable to common stockholders	\$ (1,019,855)	\$ (885,364)	\$ (6,732,312)	\$ (1,216,871)	\$ (13,774,552)
Weighted average shares outstanding:					
Basic and diluted	18,604,300	15,811,712	18,425,825	14,338,921	12,760,308

Net loss per common
share:

Basic and diluted	\$	(0.05)	\$	(0.37)	\$	(0.37)	\$	(0.08)	(1.08)
-------------------	----	--------	----	--------	----	--------	----	--------	--------

The accompanying notes are an integral part of these condensed consolidated financial statements

5

XENOMICS, INC.
(A Development Stage Company)

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY -
RESTATE**

	Common Stock Shares	Par Value	Treasury Shares	Paid in Capital	Additional Unamortized Stock-based Compensation	Deferred Development During Stage	Accumulated Deficit	Total Stockholders' Equity
Balance August 4, 1999 (Inception)	—	\$	\$	\$	\$	\$	\$	—
Sale of common stock - founders	222,000,000	22,200	—	19,800	—	—	—	42,000
Net loss for the period ended January 31, 2000	—	—	—	—	—	—	(14,760)	(14,760)
Balance, January 31, 2000	222,000,000	22,200	0	19,800	0	—	(14,760)	27,240
Net loss for the period ended January 31, 2001	—	—	—	—	—	—	(267,599)	(267,599)
Balance, January 31, 2001	222,000,000	22,200	0	19,800	0	—	(282,359)	(240,359)
Capital contribution cash				45,188				45,188
Net loss for the period ended January 31, 2002	—	—	—	—	—	—	(524,224)	(524,224)
Balance, January 31, 2002	222,000,000	22,200	0	64,988	0	—	(806,583)	(719,395)
Sale of common stock	7,548,000	755		2,645				3,400
Capital contribution cash				2,500				2,500
Net loss for the period ended January 31, 2003	—	—	—	—	—	—	(481,609)	(481,609)
Balance, January 31, 2003	229,548,000	22,955	0	70,133	0	—	(1,288,192)	(1,195,104)
Net loss for the period ended January 31, 2004	—	—	—	—	—	—	(383,021)	(383,021)
Balance, January 31, 2004	229,548,000	\$ 22,955	0	\$ 70,133	0	—	(1,671,213)	(1,578,125)

The accompanying notes are an integral part of these condensed consolidated financial statements.

XENOMICS, INC.
(A Development Stage Company)

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY -
RESTATE** (Continued)

	Common Stock Shares	Common Stock Par Value	Treasury Shares	Additional Paid in Capital	Deferred Unamortized Stock-based Compensation	Deficit Accumulated During Development Stage	Total Stockholders' Equity
Balance, January 31, 2004	229,548,000	\$ 22,955	\$ 0	\$ 70,133	\$ 0	\$ (1,671,213)	\$ (1,578,125)
Founders waive deferred compensation				1,655,029			1,655,029
Private Placement common stock	2,645,210	265		2,512,685			2,512,950
Redeemed shares from Panetta Partners, Ltd	(218,862,474)	(21,886)		(478,114)			(500,000)
Cost associated with recapitalization				(301,498)			(301,498)
Share exchange with Xenomics Founders	2,258,001	226		(226)			0
Issuance of treasury shares to escrow	350,000	35	(35)				0
Private Placement common stock	1,368,154	136		2,667,764			2,667,900
Issuance of warrants to finders				157,062			157,062
Finders warrants charged cost of capital				(157,062)			(157,062)
Deferred stock based compensation				1,937,500	(1,937,500)		0
Amortization of deferred stock based					245,697		245,697

compensation

Stock based
compensation
expense -
non-employees

3,862,007

3,862,007

Net loss for the year
ended January 31,
2005

—

—

—

—

— (5,371,027)

(5,371,027)

Balance, January 31,
2005

17,306,891 \$

1,731 \$

(35)\$

11,923,280 \$

(1,691,803)\$

(7,042,240)\$

3,190,935

The accompanying notes are an integral part of these condensed consolidated financial statements

7

XENOMICS, INC.
(A Development Stage Company)

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY -
RESTATE** (Continued)

	Preferred Stock	Common Stock Shares	Treasury Par Value Shares	Treasury Shares	Additional Paid in Capital	Deferred Unamortized Stock-based Compensation	Deficit Accumulated During Development Stage	Total Stockholders' Equity
Balance, January 31, 2005	0	17,306,891	\$ 1,731	\$ (35)	11,923,282	\$ (1,691,803)	\$ (7,042,250)	\$ 3,190,935
Private Placement common stock - February 2005		102,564	10		199,990			200,000
Payment of finders fees and expenses in cash					(179,600)			(179,600)
Common stock issued to finders	—	24,461	2	—	(2)	—	—	—
Private placement of common stock - net		127,025	12		20,388			20,400
Private Placement common stock - April 2005		1,515,384	152		2,954,847			2,954,999
Payment of finders fees and expenses in cash					(298,000)			(298,000)
Issuance of warrants to finders at fair value					222,188			222,188
Finders warrants treated cost of capital	—	—	—	—	(222,188)	—	—	(222,188)

Edgar Filing: XENOMICS INC - Form 10QSB/A

Private placement of common stock - net	1,515,384	152	2,656,847	2,656,999
Sale of Series A Convertible Preferred Stock	2,448,791		322,209	2,771,000
Accretion on Series A Convertible Preferred Stock	322,209		(322,209)	—
Value of warrants reclassified to derivative financial instrument liability	(567,085)			(567,085)
Payment of finders fees and expenses in cash			(277,102)	(277,102)
Issuance of warrants to finders at fair value			167,397	167,397
Finders warrants treated cost of capital	—	—	(167,397)	(167,397)
Sale of Series A Convertible Preferred Stock - net	\$ 2,203,915		45,107	(322,209) 1,926,813
Retirement of Treasury Shares	(350,000)	(35)	35	—
Shares issued for services	5,000		16,500	16,500
Stock based compensation expense - non-employees			2,928,298	2,928,298

Edgar Filing: XENOMICS INC - Form 10QSB/A

Amortization of deferred stock based compensation						484,374		484,294
Preferred stock dividend							(23,794)	(23,294)
Net loss for nine months ended October 31, 2005	—	—	—	—	—	—	(6,386,309)	(6,386,309)
Balance, October 31, 2005	\$ 2,203,915	18,604,300	\$ 1,860	\$ 0	\$ 17,590,422	\$ (1,207,429)	\$ (13,774,552)	\$ 4,814,216

The accompanying notes are an integral part of these condensed consolidated financial statements

XENOMICS, INC.
(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - RESTATED
(UNAUDITED)

	Nine months ended October 31,		Period from
	2005	2004	August 4, 1999 (inception) to October 31, 2005
Cash flows from operating activities:			
Net loss	\$ (6,386,309)	\$ (1,216,871)	\$ (13,428,549)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation	16,558	—	25,624
Stock based compensation expense	3,429,172	706,641	7,534,878
Founders compensation contributed to equity	—	74,404	1,655,029
Derivative financial instrument (income)	(148,611)		(148,611)
Changes in operating assets and liabilities:			
Prepaid expenses	(62,413)	(43,334)	(97,773)
Security deposit	2,475	(57,207)	(55,698)
Accounts payable and accrued expenses	(105,586)	74,356	101,472
Patent costs	—	(4,402)	—
Total adjustments	3,131,595	750,458	9,014,921
Net cash used in operating activities	(3,254,714)	(466,413)	(4,413,628)
Cash flows from investing activities:			
Acquisition of equipment	(29,575)	(88,195)	(116,138)
Net cash used in investing activities	(29,575)	(88,185)	(116,138)
Cash flows from financing activities:			
Proceeds from issuance of common stock	3,154,999	2,512,950	8,428,937
Payment of acquisition costs on common stock	(477,600)	(301,498)	(779,098)
Proceeds from issuance of preferred stock	2,771,000		2,771,000
Payment of acquisition costs on preferred stock	(277,102)		(277,102)
Purchase of common stock	—	(500,000)	(500,000)
Payment of preferred stock dividend	(23,794)	—	(23,794)
Net cash provided by financing activities	5,147,503	1,711,452	9,619,943
Net increase in cash and cash equivalents	1,863,212	1,156,844	5,090,177
Cash and cash equivalents at beginning of period			
	3,226,965	339	—
Cash and cash equivalents at end of period	\$ 5,090,177	\$ 1,157,183	\$ 5,090,177
Supplementary disclosure of cash flow information:			
Cash paid for taxes	\$ —	\$ —	\$ —
Cash paid for interest	\$ —	\$ —	\$ —

The accompanying notes are an integral part of these condensed consolidated financial statements.

XENOMICS, INC.
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

October 31, 2005

(UNAUDITED)

1. BUSINESS OVERVIEW:

Xenomics, Inc. ("Xenomics" or the "Company") is considered to be in the development stage. Since inception on August 4, 1999, Xenomics' efforts have been principally devoted to research and development, securing and protecting its patents and raising capital. From inception through October 31, 2005, Xenomics has sustained cumulative net losses of \$13,774,552. Xenomics's losses have resulted primarily from expenditures incurred in connection with salaries and facilities cost associated with research and development activities, application and filing for regulatory approval of its proposed products, patent filing and maintenance expenses, outside accounting and legal services and regulatory, scientific and financial consulting fees as well as stock-based compensation expense. From inception through October 31, 2005, Xenomics has not generated any revenue from operations, expects to incur additional losses to perform further research and development activities and does not currently have any commercial molecular diagnostic products approved by the Food and Drug Administration, and does not expect to have such for several years, if at all.

Xenomics's product development efforts are thus in their early stages and Xenomics cannot make estimates of the costs or the time it will take to complete. The risk of completion of any program is high because of the many uncertainties involved in bringing new drugs to market including the long duration of clinical testing, the specific performance of proposed products under stringent clinical testing protocols, the extended regulatory approval and review cycles and the nature and timing of costs and competing technologies being developed by organizations with significantly greater resources.

2. BASIS OF PRESENTATION:

The accompanying condensed consolidated financial statements of Xenomics, which include the results of Xenomics, Inc. a Florida corporation and its wholly owned subsidiary Xenomics, a California corporation ("Xenomics Sub"), have been prepared in accordance with (i) accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and (ii) the rules of the Securities and Exchange Commission (the "SEC") for quarterly reports on Form 10-QSB. All significant intercompany balances and transactions have been eliminated in consolidation. These condensed consolidated financial statements do not include all of the information and footnote disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with Xenomics's audited financial statements and notes thereto for the year ended January 31, 2005, included in Form 10-KSB/A filed with the SEC on January 10, 2006. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, primarily consisting of normal recurring adjustments, necessary for the fair presentation of the balance sheet and results of operations for the interim periods. The results of operations for the nine months ended October 31, 2005 are not necessarily indicative of the results of operations to be expected for the full year ending January 31, 2006.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

CASH, CASH EQUIVALENTS AND MARKETABLE INVESTMENTS - Xenomics considers all highly liquid debt instruments, including treasury bills, purchased with original maturities of three months or less to be cash equivalents.

BUSINESS CONCENTRATIONS AND CREDIT RISKS - All of Xenomics's cash and cash equivalents as of October 31, 2005 are on deposit with a major money center financial institution, or invested in short term U.S. Treasury Bills, not exceeding maturities of 180 days. Bank deposits at any point in time may exceed federally insured limits.

NET LOSS PER SHARE - Basic and diluted net loss per share is presented in conformity with SFAS No. 128, "Earnings per Share," for all periods presented. In accordance with SFAS No. 128, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Diluted weighted-average shares are the same as basic weighted-average shares since the inclusion of issuable shares pursuant to the conversion of preferred stock and the exercise of stock options and warrants would have been antidilutive.

As of October 31, 2005, Xenomics had 1,288,837 shares of common stock issuable upon conversion of the 277,100 shares of Series A convertible preferred stock outstanding. In addition Xenomics had 2,503,501 and 20,000 common stock warrants outstanding which were 100% vested as of October 31, 2005 and October 31, 2004 respectively. Stock options outstanding totaled 6,326,000 and 5,250,000 as of October 31, 2005 and 2004, respectively. All share and per share amounts have been retroactively restated to reflect the 111 for 1 stock split which was effective October 26, 2004.

ACCOUNTING FOR STOCK BASED COMPENSATION - Xenomics has adopted Statement of Financial Accounting Standard ("SFAS") No. 123, "Accounting for Stock-Based Compensation." As provided for by SFAS 123, Xenomics has elected to continue to account for its stock-based compensation programs according to the provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees ("APB 25").

A total of 5,000,000 shares of common stock have been reserved for issuance under the Xenomics Stock Option Plan, as amended (the "Plan"). As of October 31, 2005, options for 6,326,000 shares were outstanding under the Plan. 1,326,000 of such options have been granted subject to stockholder approval of an increase in the number of shares that can be granted under the Plan. With respect to the options granted prior to stockholder approval a measurement date has not occurred and accordingly no compensation expense has been recorded. When such measurement date does occur, stock based compensation expense will be recorded for any excess of the fair value on that date over the exercise price. During the nine months ended October 31, 2005, Xenomics recorded \$3,429,172 in stock-based compensation expense associated with shareholder approved options and warrants and had \$1,207,429 of deferred stock based compensation. Had the 1,326,000 options granted subject to shareholder approval been approved on October 31, 2005 (the measurement date, at which date the market price of the Company's stock was \$1.95 per share) the Company would have recognized approximately \$100,000 of additional stock-based compensation during the nine months ended October 31, 2005 and would have approximately \$600,000 of additional deferred stock based compensation as of October 31, 2005.

In December 2002, the Financial Accounting Standards Board issued SFAS No. 148, "Accounting for Stock-Based Compensation-Transition and Disclosure, an amendment of FASB Statement No. 123," to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this statement amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both Quarterly and Annual financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. (See table below).

Had compensation cost for stock options granted to employees and directors been determined based upon the fair value at the grant date for awards, consistent with the methodology prescribed under SFAS 123, Xenomics's net loss would have been as follows:

	Three Months Ended October 31,		Nine Months Ended October, 31	
	2005	2004	2005	2004
Net loss applicable to common stockholders as reported	\$ (1,019,855)	\$ (885,364)	\$ (6,732,312)	\$ (1,216,871)
Add: Stock-based employee compensation expense recorded under APB No. 25 intrinsic value method	161,458	84,239	484,375	84,239
Deduct: Stock-based employee compensation expense determined under fair value method	(324,742)	(174,239)	(974,225)	(174,388)
Pro forma net loss applicable to common stockholders	\$ (1,183,138)	\$ (975,364)	\$ (7,222,162)	\$ (1,307,020)
Net loss per share:				
Basic and diluted -as reported	\$ (0.05)	\$ (0.06)	\$ (0.37)	\$ (0.08)
Basic and diluted -pro forma	\$ (0.06)	\$ (0.06)	\$ (0.39)	\$ (0.09)
Black-Scholes Methodology Assumptions:				
Dividend yield	0%	0%	0%	0%
Risk free interest rate	4.25%	4.25%	4.25%	4.25%
Expected lives of options	7 years	7 years	7 years	7 years

Volatility of 0% was used until Xenomics's common stock began to trade publicly on July 2, 2004. Since July 5, 2004 through October 31, 2005, Xenomics has used 80% volatility to determine fair value of options granted to employees.

RECENT ACCOUNTING PRONOUNCEMENTS AFFECTING THE COMPANY - In December 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standard ("SFAS") No. 123 (Revised 2004), "Share-Based Payment." SFAS No 123R is a revision of SFAS No. 123, "Accounting for Stock-Based Compensation" and supersedes Accounting Principles Board (APB) Opinion No. 25, "Accounting for Stock Issued to Employees" and its related implementation guidance. SFAS No. 123R focuses primarily on accounting for transactions in which an entity obtains employee services through share-based payment transactions. SFAS No 123R requires a public entity to measure the cost of employee services received in exchange for the award of equity instruments based on the fair value of the award at the date of grant. The cost will be recognized over the period during which an employee is required to provide services in exchange for the award. SFAS No. 123R is effective as of the beginning of the first interim or quarterly reporting period that begins after December 15, 2005. While Xenomics cannot precisely determine the impact on net loss as a result of the adoption of SFAS No 123R, estimated compensation expense related to prior periods can be found in the above table of this footnote.

4. STOCKHOLDERS' EQUITY:

On January 28, 2005, the Company closed the first tranche of a private placement selling 1,368,154 shares of common stock and 367,681 warrants to certain investors (the "Investors"). The securities were sold as a unit (the "Units") at a price of \$1.95 per Unit for aggregate proceeds of \$2,667,900. Each Unit consisted of one share of common stock and a warrant to purchase one quarter share of common stock. The warrants are immediately exercisable at \$2.95 per share and are exercisable at any time within five years from the date of issuance. The Company issued an aggregate 123,659 warrants to purchase common stock to various selling agents, which are immediately exercisable at \$2.15 per share and will expire five years after issuance. The warrants had a fair value of \$157,062 on the date of issuance and this amount was recorded as a cost of raising capital.

On February 5, 2005 the Company completed the first tranche of the private placement described above selling an additional 102,564 shares of its common stock to the Investors at a price of \$1.95 per share for aggregate proceeds of \$200,000. In addition, the Company paid an aggregate \$179,600 in cash and issued 24,461 shares of common stock to certain selling agents, in lieu of cash, on the entire first tranche of the private placement.

On April 7, 2005, the Company closed the second and final tranche of the private placement selling 1,515,384 shares of common stock and 378,846 warrants to certain additional Investors. The securities were sold as a unit (the "Units") at a price of \$1.95 per Unit for aggregate proceeds of \$2,954,999, upon the same terms as the first tranche. The Company paid an aggregate \$298,000 and issued an aggregate 121,231 warrants to purchase common stock to various selling agents. The warrants are immediately exercisable at \$2.15 per share, will expire five years after issuance. The warrants had a fair value of \$222,188 on the date of issuance and this amount was recorded as a cost of raising capital. These April 7, 2005 Investors became parties to the same Registration Rights Agreement (the "Registration Rights Agreement") as the January 28, 2005 Investors

In connection with the offer and sale of securities to the Investors the Company also entered into a Registration Rights Agreement, dated as of January 28, 2005, with the Investors pursuant to which the Company agreed to file, within 120 days after the closing, a registration statement covering the resale of the shares of common stock sold to the Investors and the shares of common stock issuable upon exercise of the Warrants issued to the Investors. In the event a registration statement covering such shares of Common Stock is not filed with the SEC by the 120th day after the final closing of the Offering (May 28, 2005), the Company shall pay to the investors, at the Company's option in cash or common stock, an amount equal to 0.1125% of the gross proceeds raised in the Offering for each 30 day period that the registration statement is not filed with the SEC. On August 1, 2005 the Company filed a Form SB-2 registration statement with the Securities and Exchange Commission and the resulting liquidated damages in the amount of \$16,304 was paid to the Investors.

On July 2, 2004, Xenomics, Inc., formerly Used Kar Parts, Inc. acquired all of the outstanding common stock of Xenomics Sub, a then un-affiliated California corporation, by issuing 2,258,001 shares of Used Kar Parts, Inc. common stock to Xenomics Sub's five shareholders (the "Exchange"). In connection with the Exchange the Company transferred 350,000 shares of common stock to be held in escrow, in the name of the Company, to cover any undisclosed liabilities. On July 2, 2005 the Company made a determination that no escrow liability existed and these shares of common stock held in the treasury for one year were cancelled.

On July 13, 2005, the Company closed a private placement of 277,100 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") and 386,651 warrants to certain investors for aggregate gross proceeds of \$2,771,000 pursuant to a Securities Purchase Agreement dated as of July 13, 2005. The Series A Preferred Stock has a liquidation preference over common stock, earns a quarterly dividend at the rate of 1% per quarter based on the aggregate gross proceeds and is convertible into common stock at the rate of \$2.15 per share or 1,288,837 shares of common stock. The warrants sold to the Investors are immediately exercisable at \$3.25 per share and are exercisable at any time within five years from the date of issuance. These investor warrants had a fair value of \$567,085 on the date of

issuance. In addition the Company paid an aggregate \$277,102 and issued an aggregate 105,432 warrants to purchase common stock to certain selling agents. The warrants issued to the selling agents are immediately exercisable at \$2.50 per share and will expire five years after issuance. The selling agent warrants had a fair value of \$167,397 on the date of issuance and this amount was recorded as a cost of raising capital.

As per EITF 00-19, "Accounting For Derivative Financial Instruments Index to, and Potentially Settled in, Company Stock" the Company calculated the value of the warrants issued in connection with this transaction to be \$567,085. This amount was recorded as a reduction to the proceeds allocated to Preferred Stock and a corresponding liability was established. This liability has been classified as non-current since the exercise price of these warrants exceeds the market value of the related common shares. These warrants have been marked-to-market and the liability has been adjusted with a corresponding charge or benefit recorded in the statement of operations. During the three and nine month periods ending October 31, 2005, the Company recorded a benefit of \$179,663 and \$148,611, respectively.

As per EITF 00-27 "Application of Issue 98-5 to Certain Convertible Instruments" the Company evaluated the preferred stock transaction and accordingly found that there was an associated beneficial conversion feature. The cash purchase and existing conversion were found to contain a beneficial conversion feature totaling \$322,209 and the preferred stock was further discounted by this amount. The beneficial conversion amount was then accreted back to the preferred stock in accordance with the conversion provision which allowed for 100% to be converted immediately. The total amount accreted back to the preferred and charged to Deficit Accumulated During Development Stage was \$322,209 as of July 13, 2005.

In connection with the offer and sale of the Series A Preferred Stock securities the Company also entered into a Registration Rights Agreement pursuant to which the Company has agreed to have a registration statement covering the resale of the common stock attributable to conversion of Series A Preferred Stock and the shares of common stock issuable upon exercise of the preferred warrants, declared effective by October 25, 2005. In the event a registration statement covering such shares of common stock is not declared effective by October 25, 2005 the Company shall pay to the investors, at the Company's option in cash or common stock, an amount equal to 1% of the gross proceeds raised in the Offering for each 30 day period that the registration statement is not declared effective by the SEC. The registration statement filed on August 1, 2005 was not declared effective by October 25, 2005 and the resulting initial liquidated damages of \$27,710 was paid to the investors in cash on November 11, 2005. Such failure to have the registration statement declared effective by the SEC will result in continuing liquidated damages equal to \$27,710 for every 30-day period that the registration statement is not declared effective.

5. COMMITMENTS AND CONTINGENCIES:

LICENSE AGREEMENTS:

On June 28, 2005, Xenomics, the Spallanzani National Institute for Infectious Diseases (“INMI”) and SpaXen Italia, S.R.L., a joint venture between Xenomics and INMI (“SpaXen”), entered into a license agreement in which INMI granted to SpaXen an exclusive license to manufacture, have manufactured, use, import, offer to sell and/or sell products covered by certain existing and newly developed intellectual property assigned to INMI, pertaining to the application of Tr- DNA technology to the field of infectious diseases. In addition, SpaXen granted Xenomics an exclusive sublicense to manufacture, use, import and/or sell any products covered by the same INMI intellectual property licensed by SpaXen from INMI. Pursuant to the license agreement Xenomics agreed to pay to SpaXen a running royalty of 2% of the Company’s net sales of any product resulting from the licensed INMI intellectual property. SpaXen has agreed to pay INMI a running royalty of 50% of the royalty fees paid by Xenomics. SpaXen’s primary research and development targets will be tests for diagnosis of AIDS, hepatitis B, tuberculosis, malaria, and leishmaniasis diseases with the highest levels of morbidity and mortality.

EMPLOYMENT AND CONSULTING AGREEMENTS:

On June 27, 2005, Xenomics entered into an agreement with Gabriele M. Cerrone, the Company’s Co-Chairman, to serve as a consultant for a term of three years effective July 1, 2005 with automatic renewal for successive one year periods unless either party gives notice to the other not to renew the agreement. The duties of Mr. Cerrone pursuant to the agreement consist of business development, strategic planning, capital markets and corporate financing consulting advice. Mr. Cerrone’s compensation under the agreement is \$16,500 per month. Pursuant to the agreement the Company paid Mr. Cerrone a \$50,000 signing bonus in July 2005. Mr. Cerrone is eligible each year of the agreement for a cash bonus of up to 15% of his base annual compensation of \$198,000. In the event the agreement is terminated without cause or for good reason, Mr. Cerrone will receive a cash payment equal to the aggregate amount of the compensation payments for the then remaining term of the agreement. In addition, in such event, all unvested stock options owned by Mr. Cerrone will immediately vest and the exercise period of such options will be extended to the later of the longest period permitted by the Company’s stock option plans or ten years following termination. In the event a change of control of the Company occurs, Mr. Cerrone shall be entitled to such compensation upon the subsequent termination of the agreement within two years of the change in control unless such termination is the result of Mr. Cerrone's death, disability or retirement or Mr. Cerrone’s termination for cause.

On May 24, 2005, the Company’s Compensation Committee in recognition of the substantial time and effort to the Company’s affairs during the past year by each of Gabriele M. Cerrone, Co-Chairman, L. David Tomei, Co-Chairman and President of SpaXen Italia, S.R.L., the Company’s joint venture with the Spallanzani National Institute for Infectious Diseases in Rome, Italy, Samuil Umansky, President and Hovsep Melkonyan, Vice President, Research, accelerated the vesting of outstanding stock options dated June 24, 2004 previously granted to each such officer in the amounts of 1,050,000, 1,012,500, 1,012,500 and 675,000, respectively, so that such options vest as of May 24, 2005. This acceleration resulted in the Company recording stock based compensation expense of \$3,197,694 during the quarter ended July 31, 2005, which represented the balance remaining in deferred unamortized stock-based compensation.

On February 14, 2005, Xenomics entered into an employment agreement with Bernard Denoyer, pursuant to which Mr. Denoyer will serve as Vice President-Controller for a period of 1 year commencing February 14, 2005. The agreement is automatically renewed for successive 1 year periods until written notice not to renew is delivered by either us or Mr. Denoyer. Mr. Denoyer's salary is \$75,000 per year. In connection with the employment agreement, Mr. Denoyer received a grant of 75,000 incentive stock options pursuant to Xenomics's stock option plan with an exercise price of \$2.50 per share. Such options will vest at the rate of 25,000 per year for a period of three years beginning on January 14, 2006.

On December 13, 2004 Xenomics entered into a letter of engagement (the “Agreement”) with Trilogy Capital Partners, Inc. (“Trilogy”). The term of the Agreement is for twelve months and terminable thereafter by either party upon 30 days’ prior written notice. Pursuant to the Agreement, Trilogy will provide marketing, financial public relations services and assume the responsibilities of an investor relations officer. Xenomics will pay Trilogy \$10,000 per month under the Agreement.

Pursuant to the Agreement, Xenomics issued warrants to purchase 1,000,000 shares of Common Stock of Xenomics to Trilogy, at an exercise price of \$2.95 per share (the “Warrants”). The exercise price was determined to be consistent with the price of the warrants being offered to purchasers as part of an investment unit in the then operative private placement memorandum. The Warrants issued to Trilogy are exercisable upon issuance and expire on December 13, 2007. Xenomics has agreed to file a registration statement with the Securities and Exchange Commission registering for resale the shares of Common Stock underlying the Warrants. The Fair Value of the Warrants using the Black-Scholes methodology is \$2,630,440 which was recorded as stock-based compensation expense in the quarter ended January 31, 2005.

6. Restatement:

On September 2, 2005 the Company received a comment letter from the Securities and Exchange Commission (the “SEC”) concerning its Form SB-2 which was filed with the SEC by the Company on August 2, 2005. The Company’s consolidated financial statements for the year ended January 31, 2005 and the three and six months ended April 30 and July 31, 2005 included in Amendment No. 1 to Form SB-2 filed on October 28, 2005 were restated in response to certain SEC comments.

On November 28, 2005 the Company received a comment letter from the SEC concerning Amendment No. 1 to Form SB-2. The Company’s consolidated financial statements for the year ended January 31, 2005 included in Amendment No. 2 to Form SB-2 filed on January 11, 2006 were restated in response to certain SEC comments.

On February 2, 2006 the Company received a comment letter from the SEC concerning Amendment No. 2 to Form SB-2. The Company’s consolidated financial statements for the year ended October 31, 2005 and the nine months ended October 31, 2005 included in Amendment No. 3 to Form SB-2 filed on February 14, 2006 were restated in response to certain SEC comments.

On February 22, 2006 the Company received a comment letter from the SEC concerning Amendment No. 3 to Form SB-2. The Company’s consolidated financial statements for the nine months ended October 31, 2005 included in Amendment No.4 to Form SB-2 filed on February 28, 2006 were restated in response to certain SEC comments.

The following is a summary of the impact of those adjustments:

	Year Ended January 31, 2005	Nine Months Ended October 31, 2005
Net loss prior to adjustments	\$ (3,336,018)	\$ (3,248,507)
Reversal of charge for acquired in-process research and development	2,145,101	0
Stock based compensation - Trilogy Capital Partners, Inc.	(123,063)	(453,294)
Deferred founders' compensation contributed to capital	(74,404)	0
Net loss as reported in Amendment #1	(1,388,384)	(3,701,801)

Stock based compensation:		
Trilogy Capital Partners, Inc.	(2,507,377)	453,294
Consultants other than Trilogy	(1,229,568)	(2,928,298)
Employees	(245,697)	(322,916)
Other	0	(35,199)
Net loss as reported in Amendment #2	(5,371,026)	(6,534,920)
Derivative financial instrument	0	(418,474)
Net loss as reported in Amendment #3	\$ (5,371,026)	\$ (6,953,394)
Derivative financial instrument	—	567,085
Net loss as reported in Amendment #4	\$ (5,371,026)	\$ (6,386,309)
Weighted average common shares	14,580,186	18,425,825
Loss per share - Basic and diluted - Prior to adjustments	\$ (0.23)	\$ (0.18)
Loss per share - Basic and diluted - As reported in Amendment #4	\$ (0.37)	\$ (0.37)

The consolidated financial statements included in this quarterly report for the quarter and nine months ended October 31, 2005 and for the period from August 4, 1999 (inception) to October 31, 2005 reflect the cumulative effects of these adjustments. Please see Footnotes 3 and 5 above and Management's Discussion and Analysis or Plan of Operation below for more detailed discussion of stock based compensation expense and the Company's equity instruments which gave rise to the adjustments.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The following discussion should be read in conjunction with our consolidated financial statements and notes to those statements included in this Quarterly Report on Form 10-QSB. In addition to historical information, the following discussion and other parts of this Quarterly Report contain forward-looking information that involves risks and uncertainties.

OVERVIEW

We are a development stage molecular diagnostic company that focuses on the development of DNA-based tests using Trans-renal DNA ("Tr-DNA"). Tr-DNA's are fragments of DNA derived from dying cells inside the body compartment. The intact DNA is fragmented in these dying cells, appears in the blood stream and these fragments have been shown to cross the kidney barrier and can be detected in urine. Because Tr-DNA originates inside the body, using a safe and simple urine collection, we believe our patented technology can be applied to a broad range of testing including: prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease, forensic identification, drug development and bio-terrorism. In March 2004, we organized a joint venture with the Spallanzani National Institute for Infectious Diseases (Istituto Nazionale per le Malattie Infettive) in Rome, Italy, in the form of a new R&D company called SpaXen Italia, S.R.L, or SpaXen, which will conduct research and development on non-invasive diagnostic tests for infectious disease using Tr-DNA methodology.

HISTORY

Since inception on August 4, 1999 through October 31, 2005, we have sustained cumulative net losses of \$13,774,552. Our losses have resulted primarily from research and development expenses, patent costs and legal and accounting expenses. From inception through October 31, 2005, we have not generated any revenue from operations. We expect to incur additional losses to perform further research and development activities. We do not currently have any commercial products and we do not expect to have any for the foreseeable future. Our product development efforts are in their early stages and we cannot make estimates of the costs or the time it will take to complete. The risk of completion of any program is high because of the long duration of clinical testing, regulatory approval and review cycles and uncertainty of the costs. Net cash inflows from any products developed may take several years to achieve.

RESULTS OF OPERATIONS

THREE MONTHS ENDED OCTOBER 31, 2005 AND 2004.

We had no revenues during the quarters ended October 31, 2005 and 2004 because we do not have any commercial products and we do not expect to have any for the foreseeable future.

Operating expenses increased to \$1,155,647 during the quarter ended October 31, 2005 from \$889,335 for the same period in 2004. This increase occurred as a result of increased business activities which began subsequent to July 2, 2004, the date our business combination and first private placement was completed.

Research and development expenses increased \$64,933 or 22% to \$366,555 during the quarter ended October 31, 2005, from \$301,622 during the quarter ended October 31, 2004. These expenditures include our in-house research and development laboratory in New Jersey, salaries and staff costs, patent legal, filing and maintenance expenses, regulatory and scientific consulting fees and laboratory supplies. The most significant increases in the quarter were salaries and wages as we added laboratory staff in our New Jersey research facility.

General and administrative expenses increased to \$627,634 during the quarter ended October 31, 2005 as compared to \$42,402 during the quarter ended October 31, 2004. This increase was principally due to increased investor relation expenditures of approximately \$93,000; consulting fees associated with retaining the services of our Co-Chairmen, Messrs. Cerrone and Tomei totaling approximately \$104,000; plus legal and public accounting fees of approximately \$88,000; higher facilities expense, including insurance, totaling approximately \$137,000; higher compensation cost associated with the hiring of our Chief Executive Officer, Controller and other office staff of approximately \$59,000; and higher travel, primarily attending investor and scientific conferences, of \$45,000.

Stock-based compensation expense for the quarters ended October 31, 2005 and 2004 was \$161,458 and \$545,311 respectively. During the quarter ended October 31, 2004 approximately \$461,000 of such expense were attributable to options granted to our Co-Chairmen, Messrs. Cerrone and Tomei as consultants for services rendered and was measured using the fair value (Black-Scholes) methodology, where there was no such expense in the quarter ended October 31, 2005. Had we used the fair value method of computing stock-based compensation expense for employee and director options our stock based compensation expense would have been approximately \$163,000 and \$90,000 higher in the quarters ended October 31, 2005 and 2004 respectively.

Interest and investment income for the quarters ended October 31, 2005 and 2004 was \$7,633 and 3,971 respectively as a result of our higher cash and marketable investment balances reflecting our recent private placements discussed in the "Liquidity and Capital Resources" section below. In addition we incurred \$27,710 of liquidated damages to preferred shareholders associated with not having our registration statement effective by October 25, 2005.

Derivative financial instrument benefit recorded for the quarters ended October 31, 2005 and 2004 was \$179,663 and zero, respectively. This benefit is attributable to the change in the liability associated with warrants issued in connection with the financing transaction on July 13, 2005.

Net loss for the quarter ended October 31, 2005 was \$996,061 as compared to a loss of \$885,364 for the same period in 2004. The increase in the net loss in 2005 is principally the result of higher operating expenses described above.

NINE MONTHS ENDED OCTOBER 31, 2005 AND 2004.

We had no revenues during the nine months ended October 31, 2005 and 2004 because we do not have any commercial products and we do not expect to have any for the foreseeable future.

Operating expenses increased to \$6,544,349 during the nine months ended October 31, 2005 from \$1,220,842 for the same period in 2004. This increase occurred as a result of increased business activities which began subsequent to July 2, 2004, the date our business combination and first private placement was completed.

Research and development expenses increased to \$959,363 during the nine months ended October 31, 2005, up from \$469,796 during the nine months ended October 31, 2004. These expenditures include salaries and staff costs for our in-house research and development laboratory in New Jersey, patent legal, filing and maintenance expenses, regulatory and scientific consulting fees and laboratory supplies. Our research and development expenses increased because we were operating for the full nine months in the nine months ended October 31, 2005 whereas we started operating July 2, 2004 (the date of our business combination and first private placement) during the nine months ended October 31, 2004.

Similarly general and administrative expenses increased to \$2,155,814 during the nine months ended October 31, 2005 as compared to \$44,405 during the nine months ended October 31, 2004 because we were operating for the full nine months in the nine months ended October 31, 2005, whereas we started operating July 2, 2004 (the date of our business combination and first private placement) during the nine months ended October 31, 2004. This increase was principally due to increased investor relation expenditures of approximately \$470,000; higher facilities expense, including insurance and a corporate headquarters in New York City, totaling approximately \$471,000; higher compensation cost associated with the hiring of our Chief Executive Officer, Controller and other office staff of approximately \$338,000; increased consulting fees associated with retaining the services of our Co-Chairmen, Messrs. Cerrone and Tomei totaling approximately \$273,000; plus legal and public accounting fees of approximately \$270,000 and higher travel, primarily attending investor and scientific conferences, of approximately \$117,000.

Stock-based compensation expense for the nine months ended October 31, 2005 and 2004 was \$3,429,172 and \$706,641 respectively. During the nine months ended October 31, 2005 we accelerated the vesting of certain stock

options which resulted in expense of \$3,197,694 which represented the balance remaining in deferred unamortized stock-based compensation. Had we used the fair value method for employee and director options our stock based compensation expense would have been approximately \$490,000 and \$90,000 higher in the quarters ended October 31, 2005 and 2004 respectively.

Interest and investment income for the nine months ended October 31, 2005 and 2004 was \$53,443 and \$3,971 respectively as a result of our higher cash balances reflecting our recent private placements discussed in the "Liquidity and Capital Resources" section below. This income was partially offset by liquidated damages we incurred in the amount of \$16,304 to certain common stock investors for failure to file a registration statement covering such shares of common stock by the 120th day after the final closing of the private placements. On August 1, 2005 we filed the required Form SB-2 registration statement with the Securities and Exchange Commission. We also incurred \$27,710 of initial liquidated damages to preferred shareholders associated with not having our registration statement declared effective by the SEC on or prior to October 25, 2005.

Derivative financial instrument benefit recorded for the nine month ended October 31, 2005 and 2004 respectively was \$148,611 and zero, respectively. This charge is attributable to the change in the liability associated with warrants issued in connection with the financing transaction on July 13, 2005.

Net loss for the nine months ended October 31, 2005 was \$6,386,309 as compared to a loss of \$1,216,871 for the same period in 2004. The increase in the net loss in 2005 is the result of higher operating expenses, slightly offset by higher interest and investment income as described above.

Plan of Operations

We plan to devote significant financial and other resources to further research and development, and commercialize tests using our Tr-DNA technology. Our initial focus is on two key applications: prenatal genetic testing and infectious disease detection. If developed, we intend to sell these products to independent clinical laboratories and hospital laboratories approved for performance of high-complexity tests. We have completed our proof of principle studies in these two key areas and must now validate these findings in human clinical samples. It is expected that the next phase of product development will last throughout the 2006 fiscal year. The next phase requires that we gain access to clinical samples pertinent to each product focus. We have executed research contracts with North Shore - Long Island Jewish (LIJ) Health System in Lake Success, New York and Eastern Virginia Medical School in Norfolk, Virginia. The research contract with Long Island Jewish (LIJ) Health System is subject to approval by its Institutional Review Board ("IRB"). There can be no assurance that our contract with North Shore Long Island Jewish (LIJ) Health System will be approved by its IRB.

We intend to develop our infectious disease applications at SpaXen, S.R.L. our joint venture with The Spallanzani National Institute for Infectious Diseases ("INMI") located in Rome Italy. Under the terms of our agreement with INMI, INMI provides laboratory space to SpaXen and financial support in the form of chemicals and scientific personnel to work on applications of the Tr-DNA technology for a broad variety of infectious diseases. The Spallanzani Institute is a large AIDS treatment center and provides patient care to 4,000 infected patients. The SpaXen joint venture provides access to needed human clinical samples for development of our HIV and TB products. If our agreement with INMI is terminated, we may not be able to gain access to needed human clinical samples which will prevent us from developing FDA approved products and will severely limit our ability to generate revenue through product sales.

Our plan of operation is to continue our product development in our two focus areas of prenatal genetic testing and infectious disease detection with a goal toward eventually bringing FDA approved products to market. We anticipate that Tr-DNA analysis will become a platform technology for development of tests for the monitoring of tumor and pre-cancerous progression and post-treatment screening for tumor re-growth conditions. The initial opportunities for diagnostic test development are gastro-intestinal tumors, including colorectal cancer, liver cancer and pancreatic cancer. Because cancer detection and monitoring studies are long and expensive, we are actively seeking academic-based researchers who are funded to perform evaluations of new cutting-edge technologies. In this way we expect to progress our understanding of cancer detection and monitoring with little or no cost to us. We believe that our Tr-DNA technology can also be used to monitor organ transplant patients. Because organ rejection is marked by early death of cells, we believe that an early indication of rejection can be identified by measuring a unique series of genetic markers of the organ donor that can be detected in random urine samples of the organ recipient. Because organ transplant monitoring is not truly "diagnostic," in the next fiscal year we will begin to explore licensing arrangements with drug companies who manufacture the immune-suppression drugs used to prevent organ rejection. If we can conclude a license agreement, this may provide an early source of revenue for us. However, there can be no assurance that appropriate strategic partnership or licensing arrangements will be completed in either of these areas.

We expect it will take 2 to 3 years for our first product to be commercialized. During the second half of calendar 2006, with the addition of appropriate regulatory personnel, we intend to create a good manufacturing practice, or cGMP, compliant manufacturing facility. At the same time, we must adopt the FDA Quality System Regulations (QSR) system of documentation. In most cases, we expect to purchase bulk quantities of specified raw materials and reagents from qualified vendors. In some cases, we may synthesize certain materials and reagents. We expect our manufacturing facility to use bulk materials to assemble reagent sets, perform quality control testing and package the reagent sets for shipping and distribution. Because we do not have manufacturing experience, we may not be able to establish a cGMP compliant facility or develop reproducible and effective manufacturing processes at a reasonable cost. In such event, we will have to rely on third party manufacturers whose availability and cost is presently unclear.

We entered into a lease for corporate office space in New York City comprising approximately 2,000 square feet, for seven years ending September 30, 2011. We believe the lease should provide sufficient space for our corporate offices for our anticipated level of activity during 2006. In addition, we have a lease for a laboratory facility of approximately 3,700 sq. ft. in Monmouth Junction, New Jersey. As discussed above the current laboratory facility does not meet cGMP standards and we are currently assessing the cost to make the necessary modifications to the existing facility, or move to a new facility that satisfies cGMP standards.

LIQUIDITY AND CAPITAL RESOURCES.

As of October 31, 2005 we had \$5,090,177 in cash, cash equivalents and marketable investments, compared to \$3,226,965 as of January 31, 2005. This increase of \$1,863,212 is the result of net fund raising of \$5,147,504, less approximately \$3,300,000 used for operating and investing activities during the nine months ended October 31, 2005.

On January 28, 2005, we closed the first tranche of a private placement selling 1,368,154 shares of common stock and 367,681 warrants to certain investors (the "Investors"). The securities were sold as a unit (the "Units") at a price of \$1.95 per Unit for aggregate proceeds of \$2,667,900. Each Unit consisted of one share of common stock and a warrant to purchase one quarter share of common stock. The warrants are immediately exercisable at \$2.95 per share and are exercisable at any time within five years from the date of issuance. We issued an aggregate 123,659 warrants to purchase common stock to various selling agents, which are immediately exercisable at \$2.15 per share and will expire five years after issuance.

On February 5, 2005 we completed the first tranche of the private placement described above selling an additional 102,564 shares of its common stock to the Investors at a price of \$1.95 per share for aggregate proceeds of \$200,000. In addition, we paid an aggregate \$179,600 in cash and issued 24,461 shares of common stock to certain selling agents, in lieu of cash on the entire first tranche of the private placement.

On April 7, 2005, we closed the second and final tranche of the private placement selling 1,515,384 shares of common stock and 378,846 warrants to certain additional Investors for aggregate proceeds of \$2,954,999. We paid an aggregate \$298,000 in fees and issued an aggregate 121,231 warrants to purchase common stock to selling agents. The warrants are immediately exercisable at \$2.15 per share and will expire five years after issuance. These April 7, 2005 Investors became parties to the same Registration Rights Agreement as the January 28, 2005 Investors.

On July 13, 2005, we closed a private placement of 277,100 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") and 386,651 warrants to certain investors for aggregate gross proceeds of \$2,771,000 pursuant to a Securities Purchase Agreement dated as of July 13, 2005. The warrants are immediately exercisable at \$3.25 per share and are exercisable at any time within five years from the date of issuance. We paid an aggregate \$277,102 and issued an aggregate 105,432 warrants to purchase common stock to certain selling agents. The warrants issued to selling agents are immediately exercisable at \$2.50 per share and will expire five years after issuance.

Our working capital requirements will depend upon numerous factors including but not limited to the nature, cost and timing of: product development; pre-clinical and clinical testing; obtaining regulatory approvals; technological advances and our ability to establish collaborative arrangements with research organizations and individuals needed to commercialize our products. Our capital resources will be focused primarily on the clinical development and regulatory approval of our Tr-DNA technology. We expect that our existing capital resources will be sufficient to fund our operations for at least the next 12 months. We will be required to raise additional capital to complete the development and commercialization of our current product candidates.

To date, our sources of cash have been primarily limited to the sale of our equity securities. We cannot be certain that additional funding will be available on acceptable terms, or at all. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct our business. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of our product candidates.

ITEM 3: CONTROLS AND PROCEDURES.

Our Chief Executive Officer and Principal Financial Officer, based on evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) required by paragraph (b) of Rule 13a-15 or Rule 15d-15, as of October 31, 2005, have concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms. Our Chief Executive Officer and Principal Financial Officer also concluded that, as of October 31, 2005, our disclosure controls and procedures are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, to allow timely decisions regarding required disclosure.

There were no significant changes in our internal controls over financial reporting that could significantly affect internal controls during the three months ended October 31, 2005.

ITEM 6. EXHIBITS

(a) Exhibits

- 31.1 Certification of Chief Executive Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
- 31.2 Certification of Principal Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.
- 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Xenomics, Inc.
(Registrant)

Date: February 28, 2006

By: /s/ L. David Tomei

L. David Tomei
Chief Executive Officer

Date: February 28, 2006

By: /s/ Frederick Larcombe

Frederick Larcombe
Chief Financial Officer

Index to Exhibits

Exhibit	Description
31.1	<u>Certification of Chief Executive Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.</u>
31.2	<u>Certification of Principal Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.</u>
32.1	<u>Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
32.2	<u>Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>